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Background and objective: The aim of the present study was to compare intraocular   pressure 
(IOP) reduction and inflammation after selective laser trabeculoplasty (SLT) treatment in patients 
suffering from primary open angle (POAG) vs pseudoexfoliative (PXFG) glaucoma.
Study design/patients and methods: Sixty patients (60 eyes) participated in the study. 
Glaucoma patients (POAG or PXFG) scheduled for treatment with SLT were included. 
  Inflammation was measured with a laser flare meter (Kowa FM-500). Measurements were made 
before SLT and 2 hours, 1 week, and 1 month after SLT treatment. IOP was also checked at 
the same time intervals.
Results: Inflammation after SLT showed no significant difference between the groups (t-test, 
before: P = 0.16; 2 hours: P = 0.14; 1 week: P = 0.12; and 1 month: P = 0.36). IOP reduction 
was the same in both groups (t-test, P = 0.27).
Conclusion: SLT safely reduces IOP in both POAG and PXFG. Pseudoexfoliation does not 
seem to be a risk factor for post-laser complications.
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Introduction
Glaucoma is a progressive neuropathy localized in the optic nerve that may lead 
to blindness. Reducing intraocular pressure (IOP) seems to be the only treatment 
proven to slow progression in glaucoma.1 There are several methods to reduce IOP: 
pharmaceutical treatment, laser treatment, and surgery. In the Glaucoma Laser Trial 
Follow-up Study, after 7 years of follow-up, patients who had undergone argon laser 
trabeculoplasty (ALT) had lower IOP than patients on pharmaceutical treatment.2,3 
However, there has been no randomized trial comparing SLT to medical treatment. 
SLT appears to be less costly than current medical treatment.4
Argon laser trabeculoplasty (ALT) was introduced about 35 years ago and involves 
the use of a blue/green argon laser (major wavelength peaks at 488 nm and 514 nm) 
to treat the outer part of the trabecular meshwork and thereby improve aqueous 
flow and thus reduce IOP. Selective Laser Trabeculoplasty (SLT) uses a 532-nm 
  frequency-doubled, Q-switched Nd:YAG laser that delivers a low-energy, large spot, 
very brief pulse to selectively target cells of the trabecular meshwork. This “milder” 
laser application is thought to stimulate the pigmented trabecular meshwork cells and 
thus facilitate improved aqueous outflow. The exact mechanism of action for reducing 
the IOP is not known.5
Pseudoexfoliation prevalence varies between different countries. In the US, 
Karger et al6 showed an annual incidence of 25.9 per 100,000 (mean age 73) and 
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found an increased number with increasing age. Although 
pseudoexfoliation has a worldwide distribution, it appears 
more common in Scandinavia. Pseudoexfoliation prevalence 
in northern Sweden is estimated to be 23% at 66 years and 
61% at 87 years.7 Pseudoexfoliative glaucoma is estimated 
to account for around 50% of all glaucoma patients diag-
nosed in Sweden.8,9 Information regarding the influence of 
pseudoexfoliation on SLT results is scarce. Gracner et al10 
showed no difference in SLT results (IOP reduction) com-
paring pseudoexfoliative and primary open angle glaucoma 
when ten patients were followed for 18 months. Shazly et al11 
showed SLT to be safe for IOP reduction as a primary treat-
ment in PXFG. Goldenfeld et al12 showed that after SLT in 
PXFG, the amount of medication was reduced.
The aim of the present study was to compare IOP reduc-
tion and inflammation after SLT treatment in primary open 
angle glaucoma (POAG) vs pseudoexfoliative glaucoma 
(PXFG) patients.
Patients and methods
Study design
This was a prospective nonrandomized comparative study. A 
comprehensive medical and ocular history was obtained. All 
patients were asked about present inflammatory diseases and 
treatments. Ophthalmological examination was performed 
before including patients in the study. Visual acuity, IOP mea-
surements, optic nerve status, gonioscopy, and the presence 
or absence of exfoliation were registered. Visual acuity was 
recorded using a Snellen’s chart. IOP was measured using a 
Goldmann’s applanation tonometer. The optic nerve status was 
then evaluated using a 90-D lens through an undilated pupil. 
Gonioscopy was performed in a darkroom using a goniolens 
with an undilated pupil and the anterior chamber angle was 
classified into 0–IV (according to Shaffer) and pigmentation 
was classified into 0–3.13 Pupils were dilated and exfoliation 
was checked; exfoliation was registered as present or absent. 
IOP, slit-lamp, and laser flare measurements were made before 
SLT and 2 hours, 1 week, and 1 month after SLT. All included 
patients had at least two reliable visual fields showing typical 
glaucoma visual field damage. Visual fields were checked 
using the Humphrey 24-2, SITA fast program (Carl Zeiss 
Meditec, Inc, Dublin, CA). For calculations, an average of the 
values of mean deviation (MD) and visual field index (VFI) 
were calculated using the two last visual fields.
The SLT is a Q-switched, frequency-doubled Nd:YAG, 
with a wavelength around 532 nm. The SLT uses a single 
pulse (pulse duration 3 ns) and the spot size is estimated to be 
400 µm. In the present study, SLT treatment was   performed 
over 90° with the SLT Solo laser (Ellex, Australia) using some 
25–30 spots applied to the trabecular meshwork.   Traditionally, 
180° of the trabecular meshwork is treated, but a recent study14 
has shown that 90° treatment provides a similar effect. The 
initial energy used was 0.9 mJ. The energy was increased 
or decreased until bubble formation appeared and was then 
decreased by 0.1 mJ for the remainder of the treatment. The 
energy used in the present study was in the range 0.9–1.1 mJ.
All patients continued with the same medical treatment 
after SLT. No patient was treated with corticoids, NSAIDs, 
or apraclonidine before or after SLT treatment.
Inflammation was measured using a laser flare meter 
Kowa FM-500 (Kowa Europe, Düsseldorf, Germany). The 
Kowa FM-500 is based on the measurement principle of 
detecting scattered laser light. The unit of measurement 
employed by the FM-500 is photon counts per millisecond 
(pc/ms). A 1+ seen in the slit-lamp corresponds to a laser flare 
photometry value of 28.3 ± 4.8 pc/ms and a flare of 3+ to a 
value of 82.5 ± 5.2 pc/ms according to Guex-Crosier et al.15 
Herbort et al16 have shown that even normal eyes express a 
normal flare measured to be 4 pc/ms.
Study population
Patients presenting at the Glaucoma Department at the 
St Erik Eye Hospital for SLT treatment who fulfilled the 
inclusion criteria were asked to participate in the study. 
Patients were enrolled consecutively between January 2009 
and December 2009.
Every patient provided informed consent to participate 
in the study and had ample opportunity to pose questions 
to the study’s principal investigator. No direct rewards for 
participation or other incentives were given. The study was 
approved by the Ethical Committee at the Karolinska Insti-
tutet (approval number: 2009/1:1).
Inclusion criteria
•	 Patients suffering from POAG or PXFG who will be 
treated with SLT. All patients had at least two reli-
able visual fields (HFA, SITA fast) showing glaucoma 
damage.
•	 Gonioscopy: open angle defined as .grade II (Shaffer 
classification: scale 0–IV).
Exclusion criteria
•	 Patients treated with cortisone or immunosuppressive 
drugs.
•	 Patients suffering from ocular or systemic inflammatory 
diseases.
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•	 Patients who cannot be treated with SLT due to the 
eye’s characteristics (shallow anterior chamber) or bad 
collaboration.
•	 Patients treated with pilocarpine (miosis makes laser flare 
measurements very difficult).
Statistical considerations
IOP
The IOP was measured before treatment and 2 hours, 1 week, 
and 1 month after SLT in both the treated and the untreated 
eye. For statistical purposes, the authors considered the 
difference in IOP between the measurements made before 
treatment and 1 month after SLT in the treated eyes. A com-
parison was then made between the POAG and the PXFG 
groups using a double-tailed Student’s t-test.
Laser flare measurements
The laser flare measurements were performed before SLT 
and 2 hours, 1 week, and 1 month after SLT. A double-tailed 
  Student’s t-test was performed to test significance in the POAG 
vs PXFG comparison, with a significance level of 5%.
Sample size was estimated using STATA software 
(  StataCorp, College Station, TX), with a power of 95%. The 
sample size was estimated to be 26 patients in each group.
Results
Sixty patients (60 eyes) were included in the study. When 
both eyes were treated, one eye was chosen at random. 
All participants attended their appointments. The average 
age was 72.6 (SD 10.38) years. The gender distribution 
was 32 men/28 women. Each group included 16 men and 
14 women.
Regarding patient distribution, n = 30 pseudoexfoliative 
glaucoma, n = 30 open angle glaucoma (two patients in the 
PXFG group were excluded at random to make both groups 
equal). Regarding the number of SLT procedures undergone, 
n = 45 were treated with SLT for the first time; n = 8 were 
treated for the second time; and n = 7 were treated for the 
third time. All patients were treated with at least one kind of 
pressure-lowering eye drop (Table 1).
Intraocular pressure
The intraocular pressure reduction 1 month after SLT was 
6.87 mmHg in the POAG group and 6.19 mmHg in the PXFG 
group. The t-test showed no significance (P = 0.27; Figure 1).
Inflammation
Flare in the anterior chamber was measured at the four dif-
ferent time intervals: before SLT and 2 hours, 1 week, and 
1 month after SLT in both the POAG group and the PXFG 
group. No significant difference in flare was found between 
the two groups at any of the time intervals tested: (t-test, 
before: P = 0.16; 2 hours: P = 0.14; 1 week: P = 0.12; and 
1 month: P = 0.36; Figure 2).
Discussion
The present study showed no difference in IOP reduction and 
inflammation after SLT treatment when comparing POAG and 
PXFG. Scarce information was found regarding inflammation 
after SLT treatment. One of the first studies of SLT was that 
by Latina et al,17 who evaluated inflammation using the same 
device as that used in this study, the Kowa laser flare meter, and 
found significantly lower flare readings after SLT than ALT.
The absolute average (POAG + PXFG) flare values for 
treated eyes in our study after SLT treatment were around 
8 pc/ms. A 1+ seen in the slit-lamp corresponds to a laser 
IOP reduction 1 month after SLT
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Figure 1 Intraocular pressure reduction comparing before and 1 month after SLT 
treatment, the bars represent 95% confidence interval for the mean. 
Notes: t-test, P = 0.27.
Table 1 Baseline characteristics of the subjects included in the 
study
Characteristic POAG PXFG P value
Age (years) (SD) 71.60 (12.44) 75.47 (8.17) .0.05
IOP before SLT  
(mmHg) (SD)
23.52 (4.6) 24.80 (3.03) .0.05
Flare before SLT  
(pc/ms) (SD)
7.18 (3.08) 8.98 (4.8) .0.05
Average number of  
spots per eye (SD)
26.9 (4.8) 26.3 (4.6) .0.05
Average dose per  
eye (mJ) (SD)
0.89 (0.11) 0.88 (0.12) .0.05
number of  
medications (n) (SD)
1.78 (0.73) 2.04 (0.74) .0.05
Visual field MD  
(dB) (SD)
-18.1 (7.54) -16.1 (7.66) .0.05
Visual field VFI  
(%) (SD)
45 (27.7) 51.3 (24.7) .0.05
Abbreviations: IOP, intraocular pressure; MD, mean deviation; POAG, primary 
open angle glaucoma; PXFG, pseudoexfoliative glaucoma; SD, standard deviation; 
SLT, selective laser trabeculoplasty; VFI, visual field index.
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flare photometry value of 28.3 ± 4.8 pc/ms according to 
Guex-Crosier et al.15 SLT does not seem to induce clinically 
significant inflammation in our glaucoma patients. The study 
confirms previous results.18
Several studies into the effects of pseudoexfoliation in 
ALT treatment have been published. The overall results 
show quite a similar IOP reduction in POAG compared to 
PXFG.19–22 Threlkeld et al19 compared the effects of ALT 
in POAG vs PXFG and concluded that although the initial 
response to ALT in PXFG was greater, the long-term out-
come (IOP reduction) in PXFG and POAG was similar.
With regard to the effects of SLT and pseudoexfoliation, 
the results of this study agree with Shazly et al,11 who found 
a similar IOP reduction in POAG and PXFG in a long-term 
study published recently.
One of the limitations of our study was the rather 
short follow-up time. Gracner10 reported no difference in 
IOP reduction after SLT treatment comparing POAG and 
PXFG (the author followed ten patients in each group over 
18 months). The original purpose of the present study was 
to evaluate the inflammation following SLT treatment, 
so a longer follow-up would not provide any additional 
  information. According to previous studies,17,23 inflammation 
decreases 1 month after SLT treatment. Furthermore, after 
this time, some patients from each group had their glaucoma 
medication discontinued or their SLT treatment repeated and 
this could have altered the results. Considering IOP, several 
studies have indicated that IOP remains stable at 6 months17 
and 18 months.24 Therefore, the 1-month IOP values are 
likely to be predictive of future IOP control.
Another limitation could be selection bias. The St Erik Eye 
Hospital is a tertiary ophthalmic care institution, located in 
the centre of Stockholm, Sweden. The Glaucoma   Department 
serves glaucoma patients from Stockholm County as well 
as from other counties. The Glaucoma Department takes 
care of the most complicated glaucoma cases. The POAG 
patients included in the study showed advanced glaucoma 
damage (MD: -18 dB, VFI: 45%) and were perhaps not very 
representative of all POAG patients. It is possible that the 
results would have been different if patients with less visual 
field damage were included.
Pseudoexfoliation and pseudoexfoliative glaucoma are 
common findings among patients in Northern Europe.7 It was 
not difficult to recruit patients suffering from pseudoexfolia-
tive glaucoma for our study, in part due to the high pseudo-
exfoliation prevalence in Sweden, but also due to the fact 
that pseudoexfoliative glaucoma usually requires additional 
therapy and SLT seems to be a good   alternative. The energy 
used for SLT treatment in patients with pseudoexfoliation was 
the same as that used in patients without pseudoexfoliation. 
Pseudoexfoliation is often associated with increased pigmen-
tation in the trabecular meshwork. In ALT treatment, it has 
been postulated that a greater IOP reduction in PXFG than in 
POAG is probably due to the greater degree of pigmentation. 
It is possible that the thermal effect of ALT is absorbed more 
at angles containing greater amounts of melanin.21
In conclusion, SLT effectively and safely lowers IOP in 
eyes with both POAG and PXFG. Pseudoexfoliation does not 
seem to be a risk factor for post-laser complications.
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